Pancreatic Cancer Research

ResearcherBC Cancer AgencyActive in the last 2 years

David F. Schaeffer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-7341-1308; OpenAlex author ID A5104256891. Sources: OpenAlex.

Their work

Papers
47 (first author 0, last author 13)
Trials
0
Grants
0
Labs led
1
Collaborators
107
Papers, trials and grants by year

2015: 5 papers · 2016: none · 2017: 2 papers · 2018: 2 papers · 2019: 5 papers · 2020: 5 papers · 2021: 8 papers · 2022: 3 papers · 2023: 6 papers · 2024: 3 papers · 2025: 4 papers · 2026: 4 papers

Papers 47

  1. DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarc… Co-author DOI 10.1038/s41467-026-70120-z↗
  2. Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-26-0793↗
  3. Endogenous insulin mediates dynamic coordination between pancreatic cancer and systemic metabolism Co-author DOI 10.64898/2026.08.26.745597↗
  4. Parent-of-Origin-Aware Genomic Analysis to Enhance Cascade Testing in Pancreatic Cancer: A Population-Based Study Co-author DOI 10.64898/2026.10.30.26366356↗
  5. Multi-omics whole-genome characterization of the copy number landscape of metastatic pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.isci.2025.113176↗
  6. The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. Co-author DOI 10.1038/s41698-025-00888-8↗
  7. KRAS-induced STN1 (OBFC1) promotes proper CTC1-STN1-TEN1 complex-independent DNA double-strand break repair and cell cycle checkpoint maintenance in pancreatic… Co-author DOI 10.1093/nar/gkaf983↗
  8. New-onset diabetes as an emerging risk group for early detection of pancreatic cancer: current evidence, clinical challenge, and future directions. Last author DOI 10.3389/fgstr.2025.1645459↗
  9. A Deep Learning Approach for the Identification of the Molecular Subtypes of Pancreatic Ductal Adenocarcinoma Based on Whole Slide Pathology Images. Co-author DOI 10.1016/j.ajpath.2024.08.006↗
  10. Nutrient scavenging-fueled growth in pancreatic cancer depends on caveolae-mediated endocytosis under nutrient-deprived conditions. Co-author DOI 10.1126/sciadv.adj3551↗
  11. Pancreatic cancer tumor organoids exhibit subtype-specific differences in metabolic profiles. Last author DOI 10.1186/s40170-024-00357-z↗
  12. Hyperinsulinemia acts via acinar insulin receptors to initiate pancreatic cancer by increasing digestive enzyme production and inflammation. Co-author DOI 10.1016/j.cmet.2023.10.003↗
  13. Islet amyloid polypeptide does not suppress pancreatic cancer. Co-author DOI 10.1016/j.molmet.2023.101667↗
  14. Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma. Last author DOI 10.1177/17588359231157651↗
  15. Loss of ATG4B and ATG4A results in two-stage cell cycle defects in pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1242/jcs.260644↗
  16. Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.3389/fgene.2023.1282824↗
  17. Classification of Pancreatic Ductal Adenocarcinoma Using MALDI Mass Spectrometry Imaging Combined with Neural Networks. Co-author DOI 10.3390/cancers15030686↗
  18. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal a… Co-author DOI 10.1038/s41467-022-32591-8↗
  19. Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma. Co-author DOI 10.1038/s41467-022-33718-7↗
  20. Effects of hyperinsulinemia on pancreatic cancer development and the immune microenvironment revealed through single-cell transcriptomics. Co-author DOI 10.1186/s40170-022-00282-z↗
  21. Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/cam4.3695↗
  22. Stroma vs epithelium-enhanced prognostics through histologic stratification in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ijc.33304↗
  23. Reproducibility of tumor budding assessment in pancreatic cancer based on a multicenter interobserver study. Co-author DOI 10.1007/s00428-020-02987-2↗
  24. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2021.01.220↗
  25. Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma. Co-author DOI 10.1136/gutjnl-2020-320730↗
  26. Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In? Co-author DOI 10.1158/1078-0432.ccr-20-1042↗
  27. Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics. Last author DOI 10.1158/1078-0432.ccr-20-2831↗
  28. Advancing the Care of Pancreatic Cancer Patients: Moving Beyond Just Tumour Tissue. Last author DOI 10.1177/11772719211049852↗
  29. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening. Co-author DOI 10.1002/cam4.2973↗
  30. Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer. Co-author DOI 10.1016/j.xcrm.2020.100131↗
  31. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-019-0566-9↗
  32. Author Correction: Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-020-0588-3↗
  33. Altered Gene Expression along the Glycolysis-Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-19-1543↗
  34. Endogenous Hyperinsulinemia Contributes to Pancreatic Cancer Development. Co-author DOI 10.1016/j.cmet.2019.07.003↗
  35. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia. Co-author DOI 10.1053/j.gastro.2019.05.004↗
  36. Base excision repair deficiency signatures implicate germline and somatic MUTYH aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis. Co-author DOI 10.1101/mcs.a003681↗
  37. Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2017-314426↗
  38. NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-19-0191↗
  39. CDKN2A founder mutation in pancreatic ductal adenocarcinoma patients without cutaneous features of Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome. Co-author DOI 10.1186/s13053-018-0088-y↗
  40. Temporal Dynamics of Genomic Alterations in a BRCA1 Germline-Mutated Pancreatic Cancer With Low Genomic Instability Burden but Exceptional Response to Fluorour… Co-author DOI 10.1200/po.18.00057↗
  41. A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated w… Last author DOI 10.1002/cjp2.75↗
  42. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12885-017-3634-5↗
  43. Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer. Co-author DOI 10.1002/cam4.459↗
  44. Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1038/modpathol.2015.89↗
  45. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Co-author DOI 10.1038/nm.3973↗
  46. Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma. Last author DOI 10.1097/pas.0000000000000333↗
  47. The involvement of insulin-like growth factor 2 binding protein 3 (IMP3) in pancreatic cancer cell migration, invasion, and adhesion. Co-author DOI 10.1186/s12885-015-1251-8↗

Closest collaborators

The 25 strongest of 107 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel John Renouf · 39 shared papers, 2015–2026 · strength 4.92
  2. Joanna M. Karasinska · 26 shared papers, 2017–2026 · strength 3.38
  3. James Thomas Topham · 21 shared papers, 2019–2026 · strength 2.91
  4. Steve E. Kalloger · 20 shared papers, 2015–2025 · strength 2.11
  5. Jennifer Jane Knox · 14 shared papers, 2019–2026 · strength 1.65
  6. Steve Gallinger · 14 shared papers, 2015–2026 · strength 1.52
  7. Faiyaz Notta · 11 shared papers, 2020–2026 · strength 1.25
  8. Grainne Mary O'Kane · 11 shared papers, 2020–2025 · strength 1.21
  9. James D. Johnson · 6 shared papers, 2019–2026 · strength 1.09
  10. Janel L. Kopp · 6 shared papers, 2019–2026 · strength 0.92
  11. George Zogopoulos · 7 shared papers, 2020–2026 · strength 0.87
  12. Hui‐Li Wong · 10 shared papers, 2017–2022 · strength 0.85
  13. Oliver F. Bathe · 6 shared papers, 2021–2025 · strength 0.80
  14. Rachel Anne Goodwin · 5 shared papers, 2021–2025 · strength 0.64
  15. Sharlene Gill · 4 shared papers, 2019–2026 · strength 0.60
  16. Ravi Ramjeesingh · 3 shared papers, 2022–2026 · strength 0.54
  17. Mustapha Ali Tehfe · 3 shared papers, 2022–2026 · strength 0.54
  18. Petr Kavan · 3 shared papers, 2022–2026 · strength 0.54
  19. Christina Kim · 3 shared papers, 2022–2026 · strength 0.54
  20. Derek J. Jonker · 3 shared papers, 2022–2026 · strength 0.54
  21. Chris J. O’Callaghan · 3 shared papers, 2022–2026 · strength 0.54
  22. Michael K.C. Lee · 6 shared papers, 2019–2021 · strength 0.53
  23. Sandra Elisabeth Fischer · 5 shared papers, 2020–2025 · strength 0.50
  24. Robert C. Grant · 5 shared papers, 2020–2025 · strength 0.50
  25. Kasmintan A. Schrader · 5 shared papers, 2018–2026 · strength 0.48

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.